IBIO Earnings Date: Nov 11, 2026 (Estimated) — iBio, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is IBIO's next earnings date?
iBio, Inc. (IBIO) is expected to report Q1 2027 earnings on Wednesday, November 11, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.07 on revenue of $25,000.
How did IBIO do in its last earnings report?
In its most recent report on Aug 28, 2026 (Q4 2026), iBio, Inc. posted EPS of -$0.06 versus the -$0.07 estimate, a beat of 0.0%. Revenue was $0 against a $80,000 estimate. The stock's 1-day post-earnings move was -2.9%.
How much does IBIO stock move after earnings?
IBIO beat EPS estimates in 1 of its last 7 reported quarters. Over the last 8 reports the stock moved an average of 4.6% (up or down) in the day after earnings.
About iBio, Inc.
iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two distinct segments: Biopharmaceuticals and Bioprocessing. The company's leading therapeutic candidate, IBIO-100, is currently progressing through investigational new drug (IND) development, aimed at addressing systemic scleroderma and idiopathic pulmonary fibrosis. Additionally, iBio is engaged in the preclinical development of vaccine candidates, including IBIO-200 and IBIO-201, designed to prevent severe acute respiratory syndrome coronavirus 2. Another candidate, IBIO-400, is in development for the treatment of classical swine fever. Beyond its proprietary pipeline, iBio provides recombinant proteins to third parties, available both as catalog items and custom-synthesized products. It also offers comprehensive services spanning process development, advanced manufacturing, filling and finishing, and bioanalytical support. iBio maintains several strategic partnerships: a licensing agreement with Planet Biotechnology, Inc. for infectious disease therapeutics; a collaborative effort with The Texas A&M University System focused on COVID-19 vaccine candidates; a licensing pact with the University of Natural Resources and Life Sciences, Vienna; and a collaboration with CC-Pharming Ltd. Its corporate headquarters are situated in Bryan, Texas.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-28 | Q4 2026 | -0.07 | -0.06 | +0.00% | $0 | ✅ Beat | -2.86% | -7.14% | -16.43% |
| 2026-05-12 | Q3 2026 | -0.06 | -0.07 | -16.67% | $0 | ❌ Miss | -3.73% | -6.83% | +3.73% |
| 2026-02-10 | Q2 2026 | -0.07 | -0.09 | -28.57% | $0 | ❌ Miss | -2.64% | +2.64% | +9.69% |
| 2025-11-12 | Q1 2026 | -0.07 | -0.11 | -57.14% | $100,000 | ❌ Miss | -8.00% | -12.80% | +55.20% |
| 2025-09-05 | Q4 2025 | -0.25 | -0.32 | +15.79% | $200,000 | ❌ Miss | +2.92% | +18.71% | +5.94% |
| 2025-02-10 | Q2 2025 | -0.32 | -0.48 | -50.00% | $200,000 | ❌ Miss | -7.31% | +7.60% | +62.28% |
| 2024-09-20 | Q4 2024 | -0.48 | -0.91 | -89.58% | $175,000 | ❌ Miss | -6.09% | +5.58% | +56.85% |
| 2024-05-13 | Q3 2024 | — | -0.71 | — | $0 | — | +3.56% | +18.43% | +40.46% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q3 FY22 · $1.9M total
| Segment | Share | Revenue | YoY | Q1 FY21 | Q2 FY21 | Q3 FY21 | Q4 FY21 |
|---|---|---|---|---|---|---|---|
| Ibio Inc | 92.6% | $1.8M | +157.1% | $207K | $190K | $700K | $1K |
| Ibio Cdmo | 7.4% | $143K | +120.0% | $203K | $515K | $65K | $491K |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.